All articles by Joshua Silverwood

Baxter signs over kidney care arm to investment firm in $3.5bn deal

US medtech giant Baxter has announced today (13 August) the signing of a definitive agreement divesting itself of the kidney…
Purdue receives clearance for opioid overdose injector for younger individuals

Purdue Pharma’s opioid overdose reversal injection, Zurnai, was granted clearance by the US Food and Drug Administration (FDA) for use…
Explainer: Labour has been elected in the UK – now what?

Following the announcement of the UK Labour Party’s near-landslide victory on 5 July, healthcare workers and life science investors have…
UK life science industry optimistically embraces Labour victory

With a Labour party victory across the UK, the life sciences industry will be expecting Keir Starmer’s party to make…
Explainer: US Election 2024 -Biden’s healthcare outlook

As a presidential election looms in the US, the incumbent democratic party has made strides to win over public, party…

Fujifilm invests $1.2bn ramping up North Carolina facility

Japanese medtech and imaging giant Fujifilm announced an investment of $1.2bn in its large-scale cell culture as it expands its…
Regulatory changes in the US and UK to watch in 2024

Significant regulatory changes across numerous medical fields are coming in 2024 with pharmaceutical and medical device companies urged to be…
Pfizer’s multiple myeloma treatment secures conditional approval in EU

Pfizer’s Elrexfio for treating multiple myeloma has been granted conditional market approval from the European Commission (EC), following a Phase…
Bayer’s stock drops to new 18-year low after asundexian trial termination

Bayer’s stock price has plummeted to its lowest since 2005 after a clinical trial investigating the anti-coagulant drug asundexian was…
UK unveils £520m for life sciences as part of Autumn Statement 2023

The UK government has revealed its Autumn 2023 statement, introducing a raft of measures and investments including £520m ($652.9m) for…